London, 07 May 2015 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, announces that Board member Riccardo Dalla-Favera has been elected to the U.S. National Academy of Sciences.
Riccardo Dalla-Favera, MD, is the Joanne and Percy Uris Professor of Clinical Medicine and professor of pathology and cell biology in the department of genetics and development, and director, Institute for Cancer Genetics at Columbia University, New York City. He has been a leader in the field of molecular oncology and has made fundamental contributions to the field of cancer, especially in the study of the molecular genetics of B cell malignancies. As a researcher, he has contributed much of the current knowledge on the genetic lesions responsible for human B cell lymphoma, which have led to the development of diagnostic tests and are being tested as targets in clinical trials with lymphoma patients.
Gabriele Cerrone, Chairman and founder of Tiziana, commented: “I whole-heartedly congratulate Riccardo on his election to the National Academy of Sciences. This recognises his distinguished and continuing achievements in original research and is one of the most prestigious awards in science.”
The National Academy of Sciences is a private, non-profit institution that was established under a congressional charter signed by President Abraham Lincoln in 1863. It recognises achievement in science by election to membership, and - with the National Academy of Engineering, Institute of Medicine, and National Research Council - provides science, technology, and health policy advice to the federal government and other organisations.
Contacts:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder
+44 (0)20 7493 2853
Cairn Financial Advisers LLP (Nominated advisor)
Liam Murray / Avi Robinson
+44 (0)20 7148 7900
Beaufort Securities Limited (Broker)
Saif Janjua
+44 (0)20 7382 8300
FTI Consulting
Simon Conway / Rob Winder / Natalie Garland-Collins
+44 (0)20 3727 1000
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology.
In January 2015, the Company entered into an exclusive licence from Nerviano Medical Sciences relating to milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division as well as a number of other protein kinases. Milciclib is currently in phase II clinical trials for thymic carcinoma in patients previously treated with chemotherapy.
The Company also in-licensed another clinical asset in December 2014 from Novimmune. Foralumab is the only fully human engineered anti-human CD3 antibody in clinical development. This phase II asset has potential application in a wide range of autoimmune and inflammatory diseases, such as multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
Tiziana Life Sciences’ research team has discovered that Bcl-3 has a prominent role in the metastasis of mammary cancers, and has elucidated the mechanism of Bcl-3 action to be a regulator of cancer cell motility. Tiziana has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in aggressive breast cancers, but across the clinical spectrum of breast disease.
Help employers find you! Check out all the jobs and post your resume.
